PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF
ETF 13.93 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $8.79 – $24.15
- YTD
- +18.45%
- IV Rank (30D)
- 82.74
- Straddle Price
- $2.45
- P/C Vol Ratio
- 1.16
- Open
- $14.70
- Day Range
- $13.77 – $14.70
- Volume
- 38,237
- Prev Close
- $14.55
Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) ETF
No description available.
- Exchange
- ARCX
- Inception
- 2017-11-15
- Has Options
- Yes
- Expense ratio
- 0.98% prospectus, filed Mar 3, 2026
- Assets
- $16M shares × price, Nov 18, 2026
- Trailing yield
- 0.41% paid quarterly
- Average daily volume
- $978K 30 sessions
- Holdings
- 67 top 10 are 253.2%
- Listed
- Nov 15, 2017 NYSE Arca
- Last fee change
- +1 bp filed Feb 26, 2026
- Tracking difference
- -8.96 pts vs index, after fees, FY 2025
Moves with. Small caps over large (23% of its variance, beta 2.92); US large-cap stocks (14% of its variance, beta 1.61). These factors explain 42% of its daily moves over the last year.
Stated objective. The Fund seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day. (from the fund's prospectus)
All 67 holdingsFlow historySimilar fundsOverlap toolAll Leveraged Equity ETFs
- Jul 2026
- +$8K latest reported month
- Latest 3 months
- +$914K +4.4% of assets
- Latest 12 months
- −$3.9M −18.8% of assets
View as a table
| Month | Net flow |
|---|---|
| Jul 2026 | +$8K |
| Jun 2026 | +$230K |
| May 2026 | +$676K |
| Apr 2026 | −$557K |
| Mar 2026 | −$4.0M |
| Feb 2026 | −$1.3M |
| Jan 2026 | +$1.2M |
| Dec 2025 | +$14K |
| Nov 2025 | +$1.0M |
| Oct 2025 | −$792K |
| Sep 2025 | −$796K |
| Aug 2025 | +$377K |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 84 months ago
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| XPHState Street SPDR S&P Pharmaceuticals ETF | 57% | 0.35% | $508M | +25.0% | compare |
| IHEiShares U.S. Pharmaceuticals ETF | 30% | 0.37% | $1.7B | +32.0% | compare |
| PJPInvesco Pharmaceuticals ETF | 22% | 0.58% | $594M | +24.5% | compare |
| FTXHFirst Trust Nasdaq Pharmaceuticals ETF | 14% | 0.60% | $1.1B | +36.5% | compare |
| PPHVanEck Pharmaceutical ETF | 13% | 0.36% | $1.1B | +18.9% | compare |
Ranked by how much of the two portfolios is the same securities.
- Holdings vs fair value
- +18.4% 50% under, 15% over · 100% covered
- Price / earnings
- — 52% loss-making · 98% covered
- Price / book · sales
- 3.0 · 2.6 revenue growth +8.4%
- Above 200-day average
- 61% 53% above 50-day · by weight
- Short interest
- 11.4% of float, weighted · 7.3 days to cover
- Insider buying
- 6% of weight had net insider buying, 90 days; 45% net selling
- 13F holders
- +5.5% change in shares held by institutions, latest quarter
- Reporting earnings
- 0.0% of weight in 7 days; 0.0% in 14
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Exit | PCRXPACIRA BIOSCIENCES INC | 1.36% | — | — |
0 new, 0 exited, 0 increased and 0 decreased between the fund's two latest holdings reports; turnover 10.4%. Full holdings and history
- Authorized participants
- 4 active of 4 with agreements; top 3 did 95%
- Created · redeemed
- $6.5M · $9.3M over the fiscal year
- Redemptions in kind
- 100% creations 100% in kind
- Creation unit
- 50,000 shares
- Securities lending
- 2.39% of assets on loan on average; earned 2.6 bp
- Return vs index
- -8.96 pts after fees; -8.02 before
- Diversification status
- Non-diversified may concentrate in fewer issuers
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-09-22 | 2026-09-29 | $0.0009 | CD |
| 2026-06-23 | 2026-06-30 | $0.0152 | CD |
| 2026-03-24 | 2026-03-31 | $0.0109 | CD |
| 2025-12-23 | 2025-12-31 | $0.0326 | CD |
| 2025-09-23 | 2025-09-30 | $0.0098 | CD |
| 2025-06-24 | 2025-07-01 | $0.0245 | CD |
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | SPSIPH SWAP ASSET LEG | 108.07% | Derivative | — |
| — | SPSIPH SWAP ASSET LEG | 71.85% | Derivative | — |
| — | SPSIPH SWAP ASSET LEG | 54.03% | Derivative | — |
| — | GOLDMAN FINL SQ TRSRY INST 506 | 21.14% | Cash/Money Market | — |
| — | DREYFUS GOVT CASH MAN INS | 16.43% | Cash/Money Market | — |
| — | GOLDMAN SACHS FIN GOV 465 INSTITUT | 11.12% | Cash/Money Market | — |
| — | SPSIPH SWAP ASSET LEG | 9.18% | Derivative | — |
| XERS | XERIS BIOPHARMA HOLDINGS INC | 2.63% | Equity (US) | US |
| MANE | VERADERMICS INC | 1.52% | Equity (US) | US |
| LLY | ELI LILLY & CO | 1.52% | Equity (US) | US |
| VTRS | VIATRIS INC | 1.50% | Equity (US) | US |
| AMRX | AMNEAL PHARMACEUTICALS INC | 1.48% | Equity (US) | US |
| MAZE | MAZE THERAPEUTICS INC | 1.44% | Equity (US) | US |
| ZTS | ZOETIS INC | 1.37% | Equity (US) | US |
| RPRX | ROYALTY PHARMA PLC- CL A | 1.37% | Equity (Foreign) | GB |
| PRGO | PERRIGO CO PLC | 1.33% | Equity (US) | US |
| ELAN | ELANCO ANIMAL HEALTH INC | 1.32% | Equity (US) | US |
| ETON | ETON PHARMACEUTICALS INC | 1.31% | Equity (US) | US |
| COLL | COLLEGIUM PHARMACEUTICAL INC | 1.29% | Equity (US) | US |
| JNJ | JOHNSON & JOHNSON | 1.26% | Equity (US) | US |
| PFE | PFIZER INC | 1.24% | Equity (US) | US |
| LGND | LIGAND PHARMACEUTICALS | 1.23% | Equity (US) | US |
| OGN | ORGANON & CO | 1.23% | Equity (US) | US |
| JAZZ | JAZZ PHARMACEUTICALS PLC | 1.20% | Equity (Foreign) | IE |
| PBH | PRESTIGE CONSUMER HEALTHCARE | 1.19% | Equity (US) | US |
| ANIP | ANI PHARMACEUTICALS INC | 1.19% | Equity (US) | US |
| SEPN | SEPTERNA INC | 1.19% | Equity (US) | US |
| MRK | MERCK & CO. INC. | 1.17% | Equity (US) | US |
| EWTX | EDGEWISE THERAPEUTICS INC | 1.17% | Equity (US) | US |
| BMY | BRISTOL-MYERS SQUIBB CO | 1.15% | Equity (US) | US |
| TARS | TARSUS PHARMACEUTICALS INC | 1.14% | Equity (US) | US |
| AMPH | AMPHASTAR PHARMACEUTICALS IN | 1.06% | Equity (US) | US |
| INVA | INNOVIVA INC | 1.05% | Equity (US) | US |
| AMLX | AMYLYX PHARMACEUTICALS INC | 1.03% | Equity (US) | US |
| MBX | MBX BIOSCIENCES INC | 1.02% | Equity (US) | US |
| SUPN | SUPERNUS INC | 1.01% | Equity (US) | US |
| LQDA | LIQUIDIA CORP | 0.99% | Equity (US) | US |
| ELVN | ENLIVEN THERAPEUTICS INC | 0.98% | Equity (US) | US |
| TRVI | TREVI THERAPEUTICS INC | 0.98% | Equity (US) | US |
| HRMY | HARMONY BIOSCIENCES HOLDINGS | 0.96% | Equity (US) | US |
| HROW | HARROW INC | 0.95% | Equity (US) | US |
| DFTX | DEFINIUM THERAPEUTICS INC | 0.93% | Equity (US) | — |
| LBRX | LB PHARMACEUTICALS INC | 0.88% | Equity (US) | US |
| OMER | OMEROS CORP | 0.87% | Equity (US) | US |
| ZVRA | ZEVRA THERAPEUTICS INC | 0.80% | Equity (US) | US |
| AXSM | AXSOME THERAPEUTICS INC | 0.78% | Equity (US) | US |
| CORT | CORCEPT THERAPEUTICS INC | 0.73% | Equity (US) | US |
| ANRO | ALTO NEUROSCIENCE INC | 0.73% | Equity (US) | US |
| NUVB | NUVATION BIO INC | 0.72% | Equity (US) | US |
| PAHC | PHIBRO ANIMAL HEALTH CORP-A | 0.69% | Equity (US) | US |
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 32.53% | $6.7M | 3 |
| DO | 22.08% | $4.6M | 4 |
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 1.14% | -19.06% | 21.10% | 0.64% | 15.56% | -1.19% | 3.03% |
| Feb | 1.10% | -6.37% | -18.33% | 10.45% | -2.05% | 2.00% | -2.20% |
| Mar | -20.04% | 14.29% | -12.65% | -9.97% | -0.14% | -20.03% | -8.09% |
| Apr | -6.99% | -28.59% | 4.01% | -20.10% | -11.51% | 15.70% | -7.91% |
| May | 6.23% | 0.64% | -20.17% | -0.46% | -0.57% | -3.04% | -2.90% |
| Jun | 8.23% | 2.66% | 9.49% | -6.33% | -4.26% | 51.76% | 10.26% |
| Jul | -13.39% | 0.09% | 17.65% | 24.40% | 1.52% | 9.08% | 6.56% |
| Aug | -14.55% | -5.83% | 1.69% | 8.76% | 44.46% | 9.70% | 7.37% |
| Sep | -7.28% | -14.94% | -26.99% | 2.76% | 0.62% | -21.84% | -11.28% |
| Oct | -0.71% | 11.24% | -25.11% | 8.99% | 6.59% | 1.67% | 0.45% |
| Nov | -17.88% | -0.29% | 6.37% | -1.88% | 30.54% | -1.64%* | 2.54% |
| Dec | 4.61% | -15.11% | 34.78% | -20.40% | 11.92% | -- | 3.16% |
| Total | -48.83% | -51.76% | -26.34% | -11.77% | 118.81% | 28.34% | 1.41% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: PILL
Executive Summary:
Overall Assessment: BEARISH with confidence level 6/10
Key Drivers:
- Technical indicators suggest a potential reversal, as the stock price approaches the upper Bollinger Band.
- High volatility, reflected in the beta and average true range (ATR), may lead to increased market uncertainty.
Primary Risks:
- Earnings miss or negative news could exacerbate downward pressure on the stock.
- Options activity suggests a low IV rank, which may indicate historically high volatility.
Investment Thesis: PILL's recent price action is likely driven by a combination of technical and fundamental factors. The stock appears to be trading near its upper Bollinger Band, indicating potential resistance. As the stock approaches this level, I expect increased volatility and potentially even a reversal.
Recent News Sentiment Impact: None available
Technical Analysis:
Trend Direction: Medium-term downtrend (1-3 months)
Support/Resistance Levels:
- Upper Bollinger Band: $8.84
- Lower Bollinger Band: $7.39
- SMA 200: $6.61
- EMA 12: $8.19
Momentum Signals:
- RSI (14): 54.66 (neutral)
- MACD: 0.18 / Signal: 0.00 / Histogram: 0.18 (bullish)
- Bollinger Bands: neutral signal
Volume Analysis: Volume trends suggest a mixed signal, with increased volume on the recent price increase.
News & Sentiment Analysis:
Recent Headlines Summary: No recent news available
Sentiment Assessment: Neutral sentiment due to lack of recent news
Catalyst Identification: None identified
Market Narrative: The market is likely waiting for earnings or other fundamental data to drive future stock performance.
Risk & Volatility Assessment:
Beta Interpretation: High risk relative to the market (beta >1.2)
Volatility Regime: Current volatility levels are high compared to historical averages
Options Market Signals:
- IV Rank: 6.0% (Low)
- Put/Call Volume Ratio: 0.17 (Bullish sentiment)
- Options market pricing a $0.97 move by expiration
Market Context & Positioning:
Sector Performance: Neutral sector performance
Institutional Activity: Mixed institutional activity, with both buyers and sellers present
Correlation Analysis: Correlated with the market (R-squared 0.65)
Relative Valuation: Trading near its upper Bollinger Band, indicating potential resistance.
Key Levels & Action Items:
- Critical Price Levels: $8.84 (upper Bollinger Band) and $7.39 (lower Bollinger Band)
- Breakout/Breakdown Levels: None identified
- Time-Sensitive Catalysts: Earnings or other fundamental data expected to drive future stock performance
- Risk Management: Consider setting stop-loss levels at the lower Bollinger Band ($7.39) or just above the SMA 200 ($6.61).
Please note that this analysis is based on the provided data, and actual market conditions may vary.
PILL Options Activity & IV Rank
PILL IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Options Flow · All expiries
ATM Options Pricing
Chain Summary
PILL Implied Volatility
Loading implied volatility…
The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much PILL actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Estimated net dealer gamma is at the 44th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
High volatility - stock moves more than market
PILL Institutional Ownership (13F)
Filings for 2026-06-30 · 2 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Click any bar to view the full quote for that stock.
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| XERS | XERIS BIOPHARMA HOLDINGS INC | 2.63% | $16.55 | -2.59% | -0.60% | +52.39% |
| MANE | VERADERMICS INC | 1.52% | $123.89 | -0.78% | -8.43% | -10.54% |
| LLY | ELI LILLY & CO | 1.52% | $1356.61 | -1.89% | -4.95% | +3.82% |
| VTRS | VIATRIS INC | 1.50% | $19.96 | -1.58% | -3.43% | +8.01% |
| AMRX | AMNEAL PHARMACEUTICALS INC | 1.48% | $21.41 | -2.13% | -1.31% | +4.57% |
| MAZE | MAZE THERAPEUTICS INC | 1.44% | $32.16 | +3.09% | -10.88% | +0.67% |
| ZTS | ZOETIS INC | 1.37% | $82.5 | -3.58% | -0.55% | +0.62% |
| RPRX | ROYALTY PHARMA PLC- CL A | 1.37% | $68.11 | -0.81% | -1.24% | +6.85% |
| PRGO | PERRIGO CO PLC | 1.33% | $16.37 | -3.36% | +1.17% | +0.00% |
| ELAN | ELANCO ANIMAL HEALTH INC | 1.32% | $26.72 | +0.07% | +0.83% | +17.76% |
| ETON | ETON PHARMACEUTICALS INC | 1.31% | $62.31 | +0.52% | +1.41% | +24.58% |
| COLL | COLLEGIUM PHARMACEUTICAL INC | 1.29% | $25.35 | -2.24% | +1.60% | +7.87% |
| JNJ | JOHNSON & JOHNSON | 1.26% | $267.31 | -1.97% | -5.72% | -0.11% |
| PFE | PFIZER INC | 1.24% | $27.71 | -1.25% | -3.88% | -8.91% |
| LGND | LIGAND PHARMACEUTICALS | 1.23% | $291.15 | -2.53% | -7.94% | -5.42% |
| OGN | ORGANON & CO | 1.23% | $13.92 | +0.00% | +0.14% | +1.24% |
| JAZZ | JAZZ PHARMACEUTICALS PLC | 1.20% | $238.68 | -3.67% | -0.71% | +11.19% |
| PBH | PRESTIGE CONSUMER HEALTHCARE | 1.19% | $50.3 | -0.63% | +10.99% | +1.70% |
| ANIP | ANI PHARMACEUTICALS INC | 1.19% | $69.82 | -2.31% | -1.75% | -5.33% |
| SEPN | SEPTERNA INC | 1.19% | $39.96 | +1.29% | -4.54% | -2.25% |
| MRK | MERCK & CO. INC. | 1.17% | $133.1 | -3.40% | -9.42% | -9.60% |
| EWTX | EDGEWISE THERAPEUTICS INC | 1.17% | $41.65 | +0.66% | -9.11% | +4.14% |
| BMY | BRISTOL-MYERS SQUIBB CO | 1.15% | $58.87 | -1.16% | -5.54% | -6.56% |
| TARS | TARSUS PHARMACEUTICALS INC | 1.14% | $77.33 | +1.82% | +0.57% | +7.28% |
| AMPH | AMPHASTAR PHARMACEUTICALS IN | 1.06% | $28.3 | -4.73% | -1.96% | +8.70% |
| INVA | INNOVIVA INC | 1.05% | $18.37 | -0.16% | -3.16% | -12.77% |
| AMLX | AMYLYX PHARMACEUTICALS INC | 1.03% | $26.55 | -0.26% | -11.09% | -7.07% |
| MBX | MBX BIOSCIENCES INC | 1.02% | $53.99 | +1.07% | -0.95% | +7.00% |
| SUPN | SUPERNUS INC | 1.01% | $28.66 | -1.05% | -1.87% | -30.47% |
| LQDA | LIQUIDIA CORP | 0.99% | $57.16 | +1.35% | -1.65% | +44.02% |
| ELVN | ENLIVEN THERAPEUTICS INC | 0.98% | $46.69 | +4.01% | -3.35% | +11.35% |
| TRVI | TREVI THERAPEUTICS INC | 0.98% | $14.16 | +4.81% | +3.96% | +9.43% |
| HRMY | HARMONY BIOSCIENCES HOLDINGS | 0.96% | $32.91 | -0.62% | -2.65% | -8.67% |
| HROW | HARROW INC | 0.95% | $32.33 | +0.53% | +14.24% | +14.85% |
| DFTX | DEFINIUM THERAPEUTICS INC | 0.93% | $29.62 | +1.72% | -10.24% | -17.72% |
| LBRX | LB PHARMACEUTICALS INC | 0.88% | $40.34 | +0.70% | -4.99% | +2.33% |
| OMER | OMEROS CORP | 0.87% | $13.94 | -4.19% | -22.51% | -17.32% |
| ZVRA | ZEVRA THERAPEUTICS INC | 0.80% | $9.07 | -2.26% | -18.73% | -12.20% |
| AXSM | AXSOME THERAPEUTICS INC | 0.78% | $135.34 | +1.00% | -6.25% | -13.28% |
| CORT | CORCEPT THERAPEUTICS INC | 0.73% | $64.91 | -4.25% | -11.94% | -39.62% |
| ANRO | ALTO NEUROSCIENCE INC | 0.73% | $25.96 | +0.19% | -15.22% | +16.94% |
| NUVB | NUVATION BIO INC | 0.72% | $3.83 | +1.46% | -5.54% | -18.40% |
| PAHC | PHIBRO ANIMAL HEALTH CORP-A | 0.69% | $34.34 | -3.46% | -3.16% | -13.74% |
| WVE | WAVE LIFE SCIENCES INC | 0.64% | $2.75 | -0.90% | -13.00% | -18.06% |
| OCUL | OCULAR THERAPEUTIX INC | 0.63% | $5.89 | -0.76% | -6.13% | -10.82% |
| RAPP | RAPPORT THERAPEUTICS INC | 0.61% | $23.68 | +1.20% | -8.39% | -10.74% |
| ALMS | ALUMIS INC | 0.60% | $4.37 | -0.68% | -28.79% | -36.00% |
| AQST | AQUESTIVE THERAPEUTICS INC | 0.56% | $3.74 | -1.06% | +4.76% | -9.44% |
| PHAT | PHATHOM PHARMACEUTICALS INC | 0.52% | $5.14 | -3.02% | -17.50% | -26.68% |
| AVLN | AVALYN PHARMA INC | 0.51% | $27.7 | +0.04% | -9.45% | +1.65% |